Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Schaller

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Bioorganic & Medicinal Chemistry Letters|October 26, 2010
N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 inhibitors. Part 1Curt D Haffner, Stephen A Thomson, Yu Guo, et al.
Journal of Cancer Research and Clinical Oncology|August 24, 2004
Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II studyP Schmid, J Krocker, G Morack, et al.
Journal of Pediatric Surgery|January 1, 1996
Does posterior sagittal anorectoplasty in patients with high imperforate anus provide superior fecal continence?D P Bliss, D Tapper, J M Anderson, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Optimizing Ligand Efficiency of Selective Androgen Receptor Modulators (SARMs)Anthony L Handlon, Lee T Schaller, Lisa M Leesnitzer, et al.
Orphanet Journal of Rare Diseases|July 10, 2024
A rare partnership: patient community and industry collaboration to shape the impact of real-world evidence on the rare disease ecosystemT L Klein, J Bender, S Bolton, et al.
The Journal of Bone and Joint Surgery. British Volume|January 1, 1982
Improved three-year disease-free survival in osteogenic sarcomaW A Bleyer, J E Haas, P Feigl, et al.
Antimicrobial Agents and Chemotherapy|October 28, 2005
Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistanceRichard J Hazen, Robert J Harvey, Marty H St Clair, et al.
Journal of Medicinal Chemistry|January 20, 2006
Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitorKaren R Romines, George A Freeman, Lee T Schaller, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2005
Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitorRobert G Ferris, Richard J Hazen, Grace B Roberts, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2018
An orally available, brain-penetrant CAMKK2 inhibitor reduces food intake in rodent modelDaniel J Price, David H Drewry, Lee T Schaller, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry Letters|October 26, 2010
N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 inhibitors. Part 1Curt D Haffner, Stephen A Thomson, Yu Guo, et al.
Journal of Cancer Research and Clinical Oncology|August 24, 2004
Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II studyP Schmid, J Krocker, G Morack, et al.
Journal of Pediatric Surgery|January 1, 1996
Does posterior sagittal anorectoplasty in patients with high imperforate anus provide superior fecal continence?D P Bliss, D Tapper, J M Anderson, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Optimizing Ligand Efficiency of Selective Androgen Receptor Modulators (SARMs)Anthony L Handlon, Lee T Schaller, Lisa M Leesnitzer, et al.
Orphanet Journal of Rare Diseases|July 10, 2024
A rare partnership: patient community and industry collaboration to shape the impact of real-world evidence on the rare disease ecosystemT L Klein, J Bender, S Bolton, et al.
The Journal of Bone and Joint Surgery. British Volume|January 1, 1982
Improved three-year disease-free survival in osteogenic sarcomaW A Bleyer, J E Haas, P Feigl, et al.
Antimicrobial Agents and Chemotherapy|October 28, 2005
Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistanceRichard J Hazen, Robert J Harvey, Marty H St Clair, et al.
Journal of Medicinal Chemistry|January 20, 2006
Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitorKaren R Romines, George A Freeman, Lee T Schaller, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2005
Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitorRobert G Ferris, Richard J Hazen, Grace B Roberts, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2018
An orally available, brain-penetrant CAMKK2 inhibitor reduces food intake in rodent modelDaniel J Price, David H Drewry, Lee T Schaller, et al.
Pageof 6